Evidence map›Paper›PMID 29487723›Full record

ArticleOncotarget2018

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209.

Bernhard Josef Eigl, Kim Chi, Dongsheng Tu, Sebastien J Hotte, Eric Winquist, Christopher M Booth, Christina Canil, Kylea Potvin, Richard Gregg, Scott North and 10 more

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01619813 (A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer), which is not on this map. Cited by 24 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 4 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01619813 phase2completednot on this map

A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer

TypeinterventionalSponsorCanadian Cancer Trials GroupRan2012 to 2016Enrolled85ConditionsProstate CancerArmsDocetaxel, Reolysin and Prednisone, Docetaxel and Prednisone
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. The emerging role of oncolytic virotherapy in genitourinary malignancies.Frontiers in cell and developmental biology · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.International journal of molecular sciences · 2024
    Review
  14. The combination therapy of oncolytic virotherapy.Frontiers in pharmacology · 2024
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Bernhard Josef EiglBC Cancer Agency, Vancouver, BC, Canada.
Kim ChiBC Cancer Agency, Vancouver, BC, Canada.
Dongsheng TuCanadian Cancer Trials Group, Kingston, ON, Canada.
Sebastien J HotteJuravinski Cancer Centre, Hamilton, ON, Canada.
Eric WinquistLondon Health Sciences Centre, London, ON, Canada.
Christopher M BoothCancer Centre of Southeastern Ontario, Kingston, ON, Canada.
Christina CanilOttawa Regional Cancer Center, Ottawa, ON, Canada.
Kylea PotvinLondon Health Sciences Centre, London, ON, Canada.
Richard GreggCanadian Cancer Trials Group, Kingston, ON, Canada.
Scott NorthCross Cancer Centre, Edmonton, AB, Canada.
Muhammad ZulfiqarBC Cancer Agency, Vancouver, BC, Canada.
Susan EllardBC Cancer Agency, Kelowna, BC, Canada.
Joseph Dean RuetherTom Baker Cancer Centre, Calgary, AB, Canada.
Lyly LeBC Cancer Agency, Surrey, BC, Canada.
A Saranya KakumanuCancer Care Manitoba, Winnipeg, MB, Canada.
Mohammad SalimRegina Cancer Centre, Regina, SK, Canada.
Alison L AllanLondon Health Sciences Centre, London, ON, Canada.
Harriet FeilotterCanadian Cancer Trials Group, Kingston, ON, Canada.
Ashley TheisCanadian Cancer Trials Group, Kingston, ON, Canada.
Lesley SeymourCanadian Cancer Trials Group, Kingston, ON, Canada.
BC Cancer Agency · CALondon Health Sciences Centre · CACancerCare Manitoba · CAJuravinski Cancer Centre · CAOttawa Regional Cancer Foundation · CAUniversity of Regina · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPelareorep is an oncolytic virus with activity in many cancers including prostate. It has PATIENTS AND

methodsIn this randomized, open-label phase II study, patients received docetaxel 75mg/m

resultsEighty-five pts were randomized. Median age was 69, ECOG performance status was 0/1/2 in 31%/66%/3% of patients. Bone/regional lymph node/liver metastases were present in 98%/24%/6%. The median prognostic score was slightly higher in Arm A (144 vs. 129 p= 0.005). Adverse events were as expected but more prevalent in arm A. The 12-week LPD rate was 61% and 52.4% in arms A/B (p=0.51). Median survival was 19.1 on Arm A and 21.1 months on Arm B (HR 1.83; 95% CI 0.96 to 3.52; p=0.06). No survival benefit of pelareorep was found.

conclusionPelareorep with docetaxel was tolerable with comparable LPD in both arms but response and survival were inferior and so this combination does not merit further study.

Indexed as

chemotherapyclinical trialoncolytic virusesprostate cancer

Identifiers

PMID29487723
PMCPMC5814290
OpenAlexW2792539640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.